A linear rank test for use when the main interest is in differences in cure rates.
For diseases with a positive probability of being cured, a family of alternatives to the null hypothesis of equality of survival distributions is introduced, which is designed to focus power against alternatives with differences in cure rates. The optimal linear rank test for this alternative is derived, and found to be substantially more efficient than the log-rank test for this alternative when cure rates are less than 50%, while there is little difference between the tests if the cure rates are 50% or greater. The simple test based on the difference of Kaplan-Meier estimates of the proportion cured is also examined, and found to be fully efficient for this alternative with no censoring, while its efficiency rapidly drops as censoring is increased. The new test is not a pure test of equality of cure rates when the data are censored, but rather is a test of equality of survival distributions that focuses power against late differences in the survival curves.
Gray
R J
RJ
Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tsiatis
A A
AA
D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008433:Mathematics; D015233:Models, Statistical; D011336:Probability